MedTrace Logo

Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

NCT01843387 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-10-14

No results posted yet for this study

Summary

The study investigates the safety, tolerability and efficacy of a single intravenous infusion of two doses of mesenchymal precursor cells versus placebo in subjects with diabetic nephropathy and type 2 diabetes.

Conditions

Interventions

BIOLOGICAL

Mesenchymal Precursor Cells (MPCs)

Single Intravenous Infusion of MPCs Dose 1 or Placebo

BIOLOGICAL

Mesenchymal Precursor Cells (MPCs)

Single Intravenous Infusion of MPCs Dose 2 or Placebo

Sponsors & Collaborators

  • Mesoblast, Ltd.

    lead INDUSTRY

Principal Investigators

  • K Segal, PhD · Mesoblast, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-09-30
Completion
2015-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01843387 on ClinicalTrials.gov